1. Home
  2. QDEL vs GERN Comparison

QDEL vs GERN Comparison

Compare QDEL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$12.25

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.57

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
GERN
Founded
1979
1990
Country
United States
United States
Employees
N/A
229
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
QDEL
GERN
Price
$12.25
$1.57
Analyst Decision
Hold
Hold
Analyst Count
4
3
Target Price
$28.25
$2.17
AVG Volume (30 Days)
2.6M
15.4M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
45.35
N/A
EPS
N/A
N/A
Revenue
$2,730,200,000.00
N/A
Revenue This Year
$3.51
$26.91
Revenue Next Year
$3.86
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.86
$1.04
52 Week High
$37.24
$2.01

Technical Indicators

Market Signals
Indicator
QDEL
GERN
Relative Strength Index (RSI) 40.56 48.64
Support Level $10.86 $1.43
Resistance Level $17.78 $1.72
Average True Range (ATR) 0.98 0.07
MACD 0.17 -0.01
Stochastic Oscillator 21.15 31.67

Price Performance

Historical Comparison
QDEL
GERN

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: